IXICO’s New Biotech Contracts Help Drive Growth
Executive Summary
Expanding its client focus and getting smaller biotech companies on board as clients has enabled brain health imaging company IXICO to gain commercial traction this fiscal year. Subsequently, the AIM-listed firm is expecting to turn out financial results at the end of September that will exceed market expectations.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.